Preparation for a Phase 1 trial of NS-161 for inflammatory diseases
First written in FY2023-Q2. 4 of 7 entries say "Restated". Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024DroppedAnnual report
「The Phase 1 trial of NS-161 for inflammatory diseases, which had been under way since December 2022, was discontinued.」
The NS-161 Phase 1 trial for inflammatory diseases changed from ongoing to discontinued. - FY2024-Q3RestatedAnnual report
「A Phase 1 trial of NS-161 for inflammatory diseases has been under way since December 2022.」
The Phase 1 trial of NS-161 for inflammatory diseases remains under way. - FY2024-Q2RestatedAnnual report
「A Phase 1 trial of NS-161 for inflammatory diseases has been under way since December 2022.」
The Phase 1 trial of NS-161 for inflammatory diseases that began in December 2022 remains under way. - FY2024-Q1RestatedAnnual report
「A Phase 1 trial of NS-161 for inflammatory diseases has been under way since December 2022.」
The Phase 1 trial of NS-161 for inflammatory diseases that began in December 2022 remains under way. - FY2023RestatedAnnual report
「A Phase 1 trial of NS-161 for inflammatory diseases has been under way since December 2022.」
The Phase 1 trial of NS-161 for inflammatory diseases that began in December 2022 remains under way. - FY2023-Q3AdvancedAnnual report
「A Phase 1 trial of NS-161 for inflammatory diseases was initiated in December 2022.」
NS-161 progressed from the preparation stage for a Phase 1 trial for inflammatory diseases to the stage of initiating the trial in December 2022. - FY2023-Q2First statedAnnual report
「A Phase 1 trial of NS-161 is being prepared for inflammatory diseases.」
The Company stated for the first time that it was preparing a Phase 1 trial of NS-161 for inflammatory diseases.